Centers of Excellence for Translational Research (CETR) (U19 Clinical Trial Not Allowed)
ID: 351471Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $5M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351471

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-065.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the Centers of Excellence for Translational Research (CETR) program, aimed at advancing multidisciplinary research on medical countermeasures against drug-resistant bacteria and fungi. This initiative seeks to support collaborative centers that will focus on transforming basic scientific knowledge into innovative prevention, diagnosis, and treatment strategies for emerging antimicrobial resistance (AMR), with an emphasis on therapeutics, vaccines, and diagnostics. A total funding amount of $25 million is available for 3-4 grants, with individual project budgets capped at $5 million over a maximum five-year period. The application period opens on March 29, 2024, and closes on April 30, 2024; interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AI-23-065-Full-Announcement.html
    RFA-AI-23-065.html
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), seeks applications for funding under the Centers of Excellence for Translational Research (CETR) program. This initiative aims to advance multidisciplinary translational research on medical countermeasures against drug-resistant bacteria and fungi. The program emphasizes research activities that transform basic scientific knowledge into novel prevention, diagnosis, and treatment approaches for emerging antimicrobial resistance (AMR). Funding will support collaborative centers focusing on various research themes such as therapeutics, vaccines, and diagnostics targeting specific AMR pathogens. A total of $25 million is planned for 3-4 grants, with project budgets capped at $5 million over a maximum five-year period. Applications must involve a comprehensive Product Development Strategy and address regulatory challenges. The call encourages participation from diverse institutions, including historically underrepresented organizations, highlighting the importance of innovative and diverse research teams to combat public health threats posed by antibiotic resistance. The application period opens on March 29, 2024, with an expiration date set for April 30, 2024.
    Similar Opportunities
    IDeA Clinical and Translational Research Network (CTR-N) Award (P50 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the IDeA Clinical and Translational Research Network (CTR-N) Award, a federal grant aimed at enhancing clinical and translational research capacity in IDeA-eligible states and jurisdictions. This initiative seeks to develop infrastructure and human resources necessary for addressing health challenges, strengthen research competitiveness, and foster collaboration among participating organizations. The program emphasizes addressing health disparities and requires applicants to demonstrate collaborative capacity, submit an Overall Plan detailing healthcare concerns and research goals, and include a Plan for Enhancing Diverse Perspectives. The award ceiling is set at $1,300,000, with applications due by October 9, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-241.html.
    Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the Centers of Excellence in Genomic Science (CEGS) program, aimed at supporting innovative, interdisciplinary research in genomic science. This program seeks to establish academic centers that will develop transformative genomic approaches to address significant biomedical challenges, with a focus on integrating advanced technological and computational methods. Each award can provide up to $1.5 million per year for a maximum of five years, with potential renewal for an additional five years, and applications are due by June 23, 2025. Eligible applicants include a range of institutions such as higher education entities, nonprofits, and various government organizations, while foreign entities are not eligible. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Advancing Translational Sciences (NCATS), has announced the Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) funding opportunity. This grant program aims to support early-stage, high-risk exploratory research focused on developing innovative technologies that address barriers in therapeutic development, rather than targeting specific diseases or clinical trials. The initiative is designed to expedite the discovery and delivery of treatments, diagnostics, and devices to patients by fostering innovative research that can attract industry collaboration and additional funding. Eligible applicants may request up to $275,000 in direct costs over a maximum project period of two years, with applications due by June 19, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the detailed announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-177.html.
    NIH Director’s Transformative Research Awards (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce the NIH Director’s Transformative Research Awards, a federal grant opportunity aimed at supporting innovative and unconventional research projects. This program encourages individual scientists or collaborative teams to propose groundbreaking research that has the potential to redefine scientific paradigms or develop transformative technologies, without the need for preliminary data or detailed experimental plans. With an estimated total funding of $8 million and the expectation of awarding seven grants, interested applicants should prepare their proposals in advance, as applications will be solicited starting June 20, 2025, with a closing date of September 3, 2025. For further inquiries, potential applicants can contact Dr. Patricia Labosky at TransformativeAwards@mail.nih.gov or by phone at 301-594-4863.
    Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Chemical Countermeasures Research Program (CCRP) Initiative, aimed at supporting research on the harmful effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids, such as fentanyl and carfentanil. This initiative seeks to advance understanding of both immediate and delayed health impacts associated with these substances, emphasizing innovative research into toxicity mechanisms and the development of new therapeutic strategies. The program will provide up to four grants, with a maximum award of $300,000 annually over a potential five-year period, totaling an estimated $2 million in funding. Interested applicants, including various educational and nonprofit institutions, must submit their proposals by November 18, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    IDeA Clinical and Translational Research Development (CTR-D) Award (P20-Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the IDeA Clinical and Translational Research Development (CTR-D) Award (P20-Clinical Trial Optional) to enhance clinical and translational research capabilities in IDeA-eligible states. This funding opportunity aims to strengthen workforce development and improve infrastructure in health research organizations that typically have limited capacities for such research, with a focus on building research capacity and fostering collaboration within the community. Each organization can submit one application with a budget not exceeding $1.5 million over a maximum project period of five years, and successful applicants must address various cores including Administrative, Professional Development, Community Engagement, Research Design/Compliance, and Health Research, while also emphasizing diversity and inclusion in research. Interested applicants can find more information and submit their applications through the NIH ASSIST system or Grants.gov, with the application deadline set for October 9, 2025.
    NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional) to enhance research on substance use, addiction, and HIV through collaborative efforts among investigators. This program aims to integrate diverse new and early career researchers, particularly from underrepresented backgrounds, to develop innovative approaches and interdisciplinary projects that transform the scientific research landscape. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, and government entities, with a maximum project period of five years and a requirement to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested parties should note that the application deadline is November 17, 2025, and can find more information at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Limited Competition: Centers of Biomedical Research Excellence (COBRE) (Phase 3) - Transitional Centers (P30 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Limited Competition: Centers of Biomedical Research Excellence (COBRE) (Phase 3) - Transitional Centers (P30 Clinical Trial Optional)." This grant aims to support the transition of core resources and biomedical research activities at IDeA-eligible organizations into sustainable and independent operations following COBRE Phase 2 funding. The initiative is particularly significant for enhancing research capabilities and fostering inclusivity within research teams, as it requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Grants can provide up to $750,000 in annual direct costs over a five-year project period, with applications due by September 30, 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-216.html.
    Large Research Projects for Combating Antibiotic-Resistant Bacteria (CARB) (R01)
    Agency for Health Care Research and Quality
    The Agency for Healthcare Research and Quality (AHRQ) is offering a funding opportunity for Large Research Projects aimed at combating Antibiotic-Resistant Bacteria (CARB). This initiative invites applications for grant funding to enhance appropriate antibiotic use, reduce the transmission of resistant bacteria, and prevent healthcare-associated infections across various healthcare settings. With a focus on addressing significant public health threats posed by antibiotic resistance, the grants can fund projects up to $2.5 million over five years, with annual budgets not exceeding $500,000. Interested applicants must adhere to detailed submission guidelines, and the application deadline is October 30, 2026. For further inquiries, applicants can contact AHRQ at GrantQueries@ahrq.hhs.gov.
    International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)" aimed at supporting research on infectious diseases in resource-constrained countries. This initiative encourages applications from organizations based in low- and lower-middle-income economies, as classified by the World Bank, and seeks innovative proposals addressing diseases such as HIV/AIDS, tuberculosis, and malaria, with a focus on enhancing local scientific capacity. The total funding available for fiscal year 2024 is approximately $1,360,000, with individual project budgets capped at $125,000 per year for a maximum of five years. Interested applicants can find more information and submission guidelines at the NIH website, with applications accepted until August 1, 2025.